Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6528MR)

This product GTTS-WQ6528MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6528MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11654MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ3191MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ15125MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ6391MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ11706MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ5444MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ5227MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ5764MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW